Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Inclusion Criteria: * Unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC who have received one prior platinum-based chemotherapy regimen. * One prior treatment with any biologically targeted agent is acceptable * Stable, previously treated, brain metastases are allowed if clinically stable without steroid treatment for 10 days. * ECOG performance status of 0 or 1. * Measurable and/or evaluable indicator lesion(s). * Adequate hematologic, renal and hepatic function * Patient is of a legally consenting age * Patient has a life-expectancy \>2 months. * Voluntary written informed consent before performance of any study-related procedure * Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control for the duration of the study. * Male patient agrees to use an acceptable method for contraception for the duration of the study. Exclusion Criteria: * Prior treatment with pemetrexed (Alimta) or Bortezomib (Velcade). * Patient was treated for another cancer within 3 years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ. * Peripheral neuropathy NCI grade \> 2. * Symptomatic or uncontrolled brain metastasis. * Radiation therapy to major bone marrow (\> 10% of bone marrow) areas or to target lesions within 30 days prior to study entry. * Patient has received other investigational drugs with 14 days before enrollment. * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Any systemic therapy within 21 days prior to study entry. * Patient known to be human immunodeficiency virus (HIV)-positive. * Patient had a significant cardiac event within 6 months of enrollment * History of arrhythmia * Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age. * QT prolongation with other medications that required discontinuation of that medication. * Presence of left bundle branch block (LBBB). * QTc ≥480 msec or greater on screening ECG. * Patient has hypersensitivity to bortezomib, boron or mannitol. * Female patient is pregnant or breast-feeding.